{
    "success": true,
    "data": {
        "ucits": true,
        "type": "ETP",
        "leverage": true,
        "derivatives": true,
        "swaps": true,
        "inverse": false,
        "replication_method": "synthetic",
        "complex_factors": [
            "Leverage",
            "Synthetic Replication",
            "Compounding Effect",
            "High Risk Classification"
        ],
        "classification": "complex",
        "supporting_data": "The ETP Securities are designed to provide 3 times the daily performance of Moderna Inc. equity. This inherent leverage, coupled with the mention of a 'Compounding Effect' which is magnified by leverage and longer holding periods, clearly indicates complexity. The product also explicitly states that holding it for more than one day is likely to result in a return different from three times the reference asset's return over that period, which is a hallmark of leveraged, synthetic products. The risk indicator being class 7 out of 7 further supports a complex classification. While the underlying asset is a single equity security, the 3x daily leverage and the potential for amplified losses due to compounding make this product complex and difficult for retail investors to understand, especially for holding periods beyond a single day. The reference to the iSTOXX Leveraged 3x MRNA Index also points towards a synthetic replication strategy. The 'comprehension alert' at the beginning of the KID ('You are about to purchase a product that is not simple and may be difficult to understand') is a direct indicator of complexity as per MiFID II requirements."
    }
}